Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
PLD significantly prolonged PFS and induced durable responses than placebo, with a favorable safety profile, for patients with progressive or symptomatic desmoid tumors.
Authors
- Huaiyuan Xu (ORCID: https://orcid.org/0000-0002-2501-4527)
- Hongmin Chen (ORCID: https://orcid.org/0000-0001-7942-5252)
- Weiqing Chen (ORCID: https://orcid.org/0009-0004-9139-2018)
- J. Li
- Huixiong Feng (ORCID: https://orcid.org/0009-0004-9593-7011)
- Jinchang Lu
- Han Wu (ORCID: https://orcid.org/0000-0001-5269-9720)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-7089-1254)
- Qinglian Tang (ORCID: https://orcid.org/0000-0001-8632-3609)
- Guohui Song
- Anqi Wang
- Aihua Zhuang
- Jinxin Hu
- Chuangzhong Deng
- Chuanquan Deng
- Xiaojun Zhu
- Jin Wang
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3128
- Citations
- 1
- Primary Topic
- Soft tissue tumor case studies
- Type
- article
- Field-Weighted Citation Impact
- 46.80